Clinical Trial

Telemedicine XR-B for Individuals in Jail

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-06.
Trial Details
NCT Number NCT07524738
Lead Sponsor Friends Research Institute, Inc.
Conditions Opioid Use Disorder
Enrollment 30 participants
Start Date 2025-06-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-24